Skip to content

Generate Biomedicines

US · GENB #2875 by market cap Listed 2026
9.54 -0.83 -8.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:32

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 16 in the most recent period (2026/Q3).
  • Total institutional ownership rose 4.9 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
83.21% +4.85pp
Institutions
120 +16
As of
2026/Q3 vs. prior period

Holder types

VC/PE Fund53.95%
Mutual Fund19.54%
Hedge Fund5.08%
Individual/Insider4.07%
Sovereign Wealth Fund1.63%
Private Company1.51%
Endowment Fund0.87%
Public Company0.61%
Other12.73%

Top holders as of 2026-06-30

Flagship Pioneering, Inc 48.83% · 62.67M sh
FMR 5.60% · 7.19M sh
Capital Research 3.27% · 4.20M sh
Braidwell LP 2.56% · 3.28M sh
Michael Nally 2.25% · 2.89M sh
Vanguard Capital Management, LLC 1.74% · 2.24M sh
T. Rowe Price Group, Inc. 1.68% · 2.16M sh
Norges Bank Investment Management 1.63% · 2.09M sh
Banque Pictet & Cie SA 1.38% · 1.77M sh
ARK Investment Management LLC 1.53% · 1.96M sh
BlackRock 1.29% · 1.66M sh
HarbourVest Partners, LLC 1.34% · 1.72M sh
Arch Venture Partners, L.P. 1.51% · 1.94M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

43 filings tracked · 19 buys · 3 sells

NameRoleStake
Flagship Pioneering, Inc -- 48.83%
Michael Nally Chief Executive Officer 2.25%
Stéphane Bancel Independent Director 0.92%
Gevorg Grigoryan Chief Technology Officer 0.51%
Frances Arnold Independent Director 0.35%
Noubar Afeyan Co-founder & Independent Chair of the Board 0.02%
Jane Mendillo Independent Director 0.00%
Jason Silvers President 0.00%
Beth Grous Chief Human Resources Officer 0.00%
Paul Parker Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-28 Frances Arnold Independent Director Automatic Disposition -11,409 $16.19
2026-09-01 Frances Arnold Independent Director Intent to Sell (Form 144) -32,210 $16.16
2026-08-31 Frances Arnold Independent Director Automatic Disposition -1,000 $16.00
2026-03-03 Michael Nally Chief Executive Officer Open Market Acquisition +20,000 $12.00
2026-03-01 Jane Mendillo Independent Director Private Acquisition +1,500 $16.00
2026-03-01 Stéphane Bancel Independent Director Derivative Exercise and Retained +724,160 --
2026-03-01 Michael Nally Chief Executive Officer Derivative Exercise and Retained +658,327 --
2026-03-01 Beth Grous Chief Human Resources Officer Private Acquisition +300 $16.00
2026-03-01 Jason Silvers President Private Acquisition +2,000 $16.00
2026-02-25 Flagship Pioneering, Inc -- Initial Statement of Beneficial 0 --
2026-02-25 Noubar Afeyan Co-founder & Independent Chair of the Board Initial Statement of Beneficial 0 --
2026-02-25 Paul Parker Independent Director Other Derivative Acquisition +29,561 $16.00
2026-02-25 Paul Parker Independent Director Initial Statement of Beneficial 0 --
2026-02-25 Marsha Fanucci Independent Director Other Derivative Acquisition +29,561 $16.00
2026-02-25 Marsha Fanucci Independent Director Initial Statement of Beneficial 0 --
2026-02-25 Nancy Simonian Independent Director Other Derivative Acquisition +29,561 $16.00
2026-02-25 Nancy Simonian Independent Director Initial Statement of Beneficial 0 --
2026-02-25 Frances Arnold Independent Director Other Derivative Acquisition +29,561 $16.00
2026-02-25 Frances Arnold Independent Director Initial Statement of Beneficial 0 --
2026-02-25 Jane Mendillo Independent Director Other Derivative Acquisition +29,561 $16.00

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.

Generate Biomedicines discussion 0 comments

Add a comment